A randomized study on postrelapse disease-free survival with adjuvant mistletoe versus oral etoposide in osteosarcoma patients

Evidence-based Complementary and Alternative Medicine

Volumn 2014, Issue , 2014, Pages

  Longhi, Alessandra ^a   Reif, Marcus ^b   Mariani, Erminia ^a   Ferrari, Stefano ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b Institute for Clinical Research (IKF)   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; VISCUM ALBUM EXTRACT;

ADOLESCENT; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; HUMAN; IMMUNOMODULATION; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OSTEOSARCOMA; OUTCOME ASSESSMENT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TREATMENT DURATION; VISCUM ALBUM;

EID: 84899462006     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2014/210198     Document Type: Article

References (42)

1. Briccoli A., Rocca M., Salone M., Bacci G., Ferrari S., Balladelli A., Mercuri M., Resection of recurrent pulmonary metastases in patients with osteosarcoma. Cancer 2005 104 8 1721 1725 2-s2.0-26444584891 10.1002/cncr.21369
2. Fagioli F., Aglietta M., Tienghi A., Ferrari S., Brach del Prever A., Vassallo E., Palmero A., Biasin E., Bacci G., Picci P., Madon E., High-dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian Sarcoma Group study. Journal of Clinical Oncology 2002 20 8 2150 2156 2-s2.0-0037089598 10.1200/JCO.2002.08.081
3. Bacci G., Briccoli A., Longhi A., Ferrari S., Mercuri M., Faggioli F., Versari M., Picci P., Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. Acta Oncologica 2005 44 7 748 755 2-s2.0-27544499184 10.1080/02841860500327503
4. Ritter J., Bielack S. S., Osteosarcoma. Annals of Oncology 2010 21 supplement 7 vii320 vii325 2-s2.0-78649343858 10.1093/annonc/mdq276
5. Leary S. E., Wozniak A. W., Billups C. A., Wu J., McPherson V., Neel M. D., Rao B. N., Daw N. C., Survival of pediatric patients after relapsed osteosarcoma: the St. Jude Children's Research Hospital experience. Cancer 2013 119 14 2645 2653 10.1002/cncr.28111
6. EURAMOS-1, A randomized trial of the European and American Osteosarcoma Study Group to optimize treatment strategies for resectable osteosarcoma based on histological response to pre-operative chemotherapy. ISRCTN67613327, 2009, https://www.skion.nl/workspace/uploads/euramos-1-protocol-v2-1-2009-04-21.pdf
7. Kebudi R., Görgün Ö., Ayan I., Oral etoposide for recurrent/progressive sarcomas of childhood. Pediatric Blood and Cancer 2004 42 4 320 324 2-s2.0-1542267857 10.1002/pbc.10393
8. Sandri A., Massimino M., Mastrodicasa L., Sardi N., Bertin D., Basso M. E., Todisco L., Paglino A., Perilongo G., Genitori L., Valentini L., Ricardi U., Gandola L., Giangaspero F., Madon E., Treatment with oral etoposide for childhood recurrent ependymomas. Journal of Pediatric Hematology/Oncology 2005 27 9 486 490 2-s2.0-25844463600 10.1097/01.mph.0000181430.71176.b7
9. Hugo F., Dittmar T., Treutler E. K., Zänker K. S., Kuehn J. J., The Viscum album extract Iscador P does not cause an autocrine interleukin-6 loop in B-Non-Hodgkin's lymphoma cell lines. Onkologie 2005 28 8-9 415 420 2-s2.0-27644532725 10.1159/000086343
10. Mueller E. A., Anderer F. A., A Viscum album oligosaccharide activating human natural cytotoxicity is an interferon γ inducer. Cancer Immunology Immunotherapy 1990 32 4 221 227 2-s2.0-0025642937 10.1007/BF01741704
11. Braun J. M., Ko H. L., Schierholz J. M., Beuth J., Standardized mistletoe extract augments immune response and down-regulates local and metastatic tumor growth in murine models. Anticancer Research 2002 22 6 4187 4190 2-s2.0-0036875696
12. Schaffrath B., Mengs U., Schwarz T., Hilgers R. D., Beuth J., Möckel B., Lentzen H., Gerstmayer B., Anticancer activity of rViscumin (recombinant mistletoe lectin) in tumor colonization models with immunocompetent mice. Anticancer Research 2001 21 6 3981 3987 2-s2.0-0035569140
13. Kuttan G., Menon L. G., Antony S., Kuttan R., Anticarcinogenic and antimetastatic activity of Iscador. Anti-Cancer Drugs 1997 8 1 S15 S16 2-s2.0-0031009207
14. Hajto T., Hostanska K., Frei K., Rordorf C., Gabius H.-J., Increased secretion of tumor necrosis factor interleukin 1, and interleukin 6 by human mononuclear cells exposed to β -galactoside-specific lectin from clinically applied mistletoe extract. Cancer Research 1990 50 11 3322 3326 2-s2.0-0025313821
15. Chernyshov V. P., Heusser P., Omelchenko L. I., Chernyshova L. I., Vodyanik M. A., Vykhovanets E. V., Galazyuk L. V., Pochinok T. V., Gaiday N. V., Gumenyuk M. E., Zelinsky G. M., Schaefermeyer H., Schaefermeyer G., Immunomodulatory and clinical effects of Viscum album (Iscador M and Iscador P) in children with recurrent respiratory infections as a result of the chernobyl nuclear accident. American Journal of Therapeutics 2000 7 3 195 203 2-s2.0-0034189813
16. Kienle G. S., Berrino F., Büssing A., Portalupi E., Rosenzweig S., Kiene H., Mistletoe in cancer-a systematic review on controlled clinical trials. European Journal of Medical Research 2003 8 3 109 119 2-s2.0-0242309722
17. Möckel B., Schwarz T., Zinke H., Eck J., Langer M., Lentzen H., Effects of mistletoe lectin I on human blood cell lines and peripheral blood cells-cytotoxicity, apoptosis and induction of cytokines. Arzneimittel- Forschung/Drug Research 1997 47 10 1145 1151 2-s2.0-0030853637
18. van Huyen J.-P. D., Bayry J., Delignat S., Gaston A. T., Michel O., Bruneval P., Kazatchkine M. D., Nicoletti A., Kaveri S. V., Induction of apoptosis of endothelial cells by Viscum album: a role for anti-tumoral properties of mistletoe lectins. Molecular Medicine 2002 8 10 600 606 2-s2.0-0036821227
19. Harmsma M., Ummelen M., Dignef W., Tusenius K. J., Ramaekers F. C. S., Effects of mistletoe (Viscum album L.) extracts Iscador on cell cycle and survival of tumor cells. Arzneimittel-Forschung/Drug Research 2006 56 6 474 482 2-s2.0-33748636232
20. Hajtò T., Berki T., Pàlinkàs L., Boldizsàr F., Németh P., Investigation of the effect of mistletoe (Viscum album L.) extract Iscador on the proliferation and apoptosis of murine thymocytes. Arzneimittel-Forschung/Drug Research 2006 56 6 441 446 10.1055/s-0031-1296810
21. Schöffski P., Riggert S., Fumoleau P., Campone M., Bolte O., Marreaud S., Lacombe D., Baron B., Herold M., Zwierzina H., Wilhelm-Ogunbiyi K., Lentzen H., Twelves C., Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for research and treatment of cancer new drug development group. Annals of Oncology 2004 15 12 1816 1824 2-s2.0-19944387235 10.1093/annonc/mdh469
22. Longhi A., Mariani E., Kuehn J. J., A randomized study with adjuvant mistletoe versus oral Etoposide on post relapse disease-free survival in osteosarcoma patients. European Journal of Integrative Medicine 2009 1 1 31 39 2-s2.0-63249129508 10.1016/j.eujim.2009.02.005
23. Stein G. M., Meink H., Durst J., Berg P. A., Release of cytokines by a fermented lectin-1 (ML-1) free mistletoe extract reflects differences in the reactivity of PBMC in healthy and allergic individuals and tumour patients. European Journal of Clinical Pharmacology 1996 51 3-4 247 252 2-s2.0-0030472252 10.1007/s002280050192
24. Mueller E. A., Hamprecht K., Anderer F. A., Biochemical characterization of a component in extracts of Viscum album enhancing human NK cytotoxicity. Immunopharmacology 1989 17 1 11 18 2-s2.0-0024598839
25. Stein G. M., Berg P. A., Flow cytometric analyses of the specific activation of peripheral blood mononuclear cells from healthy donors after in vitro stimulation with a fermented mistletoe extract and mistletoe lectins. European Journal of Cancer 1998 34 7 1105 1110 2-s2.0-0032103912 10.1016/S0959-8049(98)00044-6
26. Stein G. M., Büssing A., Schietzel M., Stimulation of the maturation of dendritic cells in vitro by a fermented mistletoe extract. Anticancer Research 2002 22 6 4215 4219 2-s2.0-0036875802
27. Mossalayi M. D., Alkharrat A., Malvy D., Nitric oxide involvement in the anti-tumor effect of mistletoe (Viscum album L.) extracts iscador on human macrophages: short communication. Arzneimittel-Forschung/Drug Research 2006 56 6 457 460 2-s2.0-33748668667
28. Clopper C. J., Pearson E. S., The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934 26 4 404 413 10.1093/biomet/26.4.404
29. Blair G. E., Cook G. P., Cancer and the immune system: an overview. Oncogene 2008 27 45, article 5868 2-s2.0-53549083526 10.1038/onc.2008.277
30. Jeys L. M., Grimer R. J., Carter S. R., Tillman R. M., Abudu A., Post operative infection and increased survival in osteosarcoma patients: are they associated? Annals of Surgical Oncology 2007 14 10 2887 2895 2-s2.0-34648820468 10.1245/s10434-007-9483-8
31. Müller C. R., Smeland S., Bauer H. C. F., Sæter G., Strander H., Interferon- as the only adjuvant treatment in high-grade osteosarcoma: long term results of the Karolinska Hospital series. Acta Oncologica 2005 44 5 475 480 2-s2.0-23944474283 10.1080/02841860510029978
32. Meyers P. A., Schwartz C. L., Krailo M. D., Healey J. H., Bernstein M. L., Betcher D., Ferguson W. S., Gebhardt M. C., Goorin A. M., Harris M., Kleinerman E., Link M. P., Nadel H., Nieder M., Siegal G. P., Weiner M. A., Wells R. J., Womer R. B., Grier H. E., Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the children's oncology group. Journal of Clinical Oncology 2008 26 4 633 638 2-s2.0-39149136228 10.1200/JCO.2008.14.0095
33. Weleda A. G., Iscador in Cancer Therapy. Recommendations for Treatment 2013 3rd Arlesheim, Switzerland Weleda AG Medical Affairs, Schwäbisch- Gmünd, Germany, Society for Cancer Research
34. Janssen O., Scheffler A., Kabelitz D., In vitro effects of mistletoe extracts and mistletoe lectins. Cytotoxicity towards tumor cells due to the induction of programmed cell death (apoptosis). Arzneimittel-Forschung/Drug Research 1993 43 11 1221 1227 2-s2.0-0027374994
35. Büssing A., Suzart K., Bergmann J., Pfüller U., Schietzel M., Schweizer K., Induction of apoptosis in human lymphocytes treated with Viscum album L. is mediated by the mistletoe lectins. Cancer Letters 1996 99 1 59 72 2-s2.0-0042608534 10.1016/0304-3835(95)04038-2
36. Büssing A., Vervecken W., Wagner M., Wagner B., Pfüller U., Schietzel M., Expression of mitochondrial Apo2.7 molecules and Caspase-3 activation in human lymphocytes treated with the ribosome-inhibiting mistletoe lectins and the cell membrane permeabilizing viscotoxins. Cytometry 1999 37 2 133 139
37. Stein G. M., Berg P. A., Immunmodulation durch Mistelextrakte: ergebnisse von in vitro und ex vivo Studien (abstract). Der Merkurstab 1997 50 2 35
38. Büssing A., Schaller G., Pfüller U., Generation of reactive oxygen intermediates (ROI) by the thionins from Viscum album L. Anticancer Research 1998 18 6 4291 4296 2-s2.0-0032421879
39. Tabiasco J., Pont F., Fournié J.-J., Vercellone A., Mistletoe viscotoxins increase natural killer cell-mediated cytotoxicity. European Journal of Biochemistry 2002 269 10 2591 2600 2-s2.0-0036111768 10.1046/j.1432-1033. 2002.02932.x
40. Kuttan G., Vasudevan D. M., Kuttan R., Isolation and identification of a tumour reducing component from mistletoe extract (Iscador). Cancer Letters 1988 41 3 307 314 2-s2.0-0023805951
41. Becker H., Exner J., Vergleichende Untersuchungen von Misteln verschiedener Wirtsbäume an Hand der Flavonoide and Phenolcarbonsä uren. Zeitschrift für Pflanzenphysiologie 1980 97 5 417 428 10.1016/S0044-328X(80)80016-X
42. Sekeroǧlu Z. A., Sekeroǧlu V., Effects of Viscum album L. extract and quercetin on methotrexate-induced cyto-genotoxicity in mouse bone-marrow cells. Mutation Research 2012 746 1 56 59 10.1016/j.mrgentox.2012. 02.012